在中东和北非裔美国人中疑似未被诊断的ADRD
Tiffany B Kindratt1, Kristine J Ajrouch2,3, Laura B Zahodne3,4
1Public Health Program, Department of Kinesiology, College of Nursing and Health Innovation, University of Texas at Arlington, 500 West Nedderman Drive, Arlington, TX, 76019, USA. tiffany.kindratt@uta.edu.
Journal of immigrant and minority health
|June 23, 2023
概括
中东和北非 (MENA) 血统的成年人患阿尔茨海默病和相关痴呆症 (ADRD) 的未确诊率最高. 与白人女性相比,中东和北非血统的女性面临的未被诊断的ADRD的几率明显更高.
科学领域:
- 老年学是指老年学的学科.
- 公共卫生 公共卫生
- 健康差异 在健康上的差异
背景情况:
- 阿尔茨海默病和相关痴呆症 (ADRD) 的低诊断是少数群体中已知的问题,特别影响女性.
- 现有的研究还没有充分探讨中东和北非 (MENA) 人口中的这些差异.
研究的目的:
- 估计美国中东北非裔成年人中未被诊断的ADRD的患病率.
- 为了比较MENA成年人和非西班牙裔白人 (美国出生的和外国出生的) 之间的ADRD低诊断率.
- 分析这些群体内未被诊断的ADRD的性别分层差异.
主要方法:
- 利用了来自国家健康访谈调查 (2000-2017年) 和医疗支出小组调查 (2001-2018年) 的链接数据.
- 包括65岁及以上的参与者 (n=23,981).
- 通过识别报告认知限制而没有正式ADRD诊断的个体来确定未被诊断的ADRD.
主要成果:
- 中东和北非血统的成年人表现出未诊断的ADRD的最高率为15.8%,相比之下,美国出生的非西班牙裔白人 (8.1%) 和外国出生的非西班牙裔白人 (11.8%).
- 与美国出生的白人女性相比,中东和北非血统的女性患有未诊断的ADRD的几率是美国出生的白人女性的2.52倍,即使调整了风险因素.
- 这项研究为MENA成年人提供了第一个未被诊断的ADRD的国家估计.
结论:
- 在MENA血统的成年人中存在ADRD低诊断的显著差异,特别是在女性中.
- 研究结果强调需要有针对性的研究和政策干预措施来解决健康不平等问题.
- 进一步调查对于改善医疗保健资源分配和解决痴呆症诊断方面的差异至关重要.
更多相关视频
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
32.5K
12:18A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
7.6K
相关概念视频
01:26Alzheimer's Disease: Overview
530
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
530
01:22Alzheimer's Disease: Treatment
222
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
222
01:30Dementia
142
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
142